GLP-1RAs and the Dermatologist

Glucagon-like peptide 1 receptor ago­ nists (GLP-1RAs) have shifted how we approach chronic disease, both within and beyond dermatology. Originally developed for the treatment of type 2 diabetes, GLP-1RA medications such as semaglutide and tirzepatide are now at the center of a broader conversation about weight management, inflamma­ tion, and multi-system disease modification. Dermatologists are uniquely positioned to understand and potentially lever­ age the anti-inflammatory and systemic benefits of these agents.

GLP-1RAs demonstrate a powerful capacity for weight loss, but their relevance in dermatology extends further. Weight reduction can improve inflammatory dermatoses such as psoriasis and hidradenitis suppurativa, both of which are frequently associated with metabolic syndrome and cardiovascular comorbidities. Additionally, emerging data suggest these agents may possess intrinsic anti-inflammatory effects, offering potential therapeutic benefit even beyond their impact on body mass. Their ability to modulate sys­ temic inflammation may, in the future, help reduce the bur­den of inflammatory arthritis and even cardiovascular risks linked to chronic dermatologic conditions.

Appropriate incorporation of GLP-1RAs into dermatologic care requires a solid understanding of their mechanism of action, possible side effects, and interactions with procedural and pharmacologic treatments. As with any new class of medication, familiarity breeds safety and confidence. We must approach these agents with both curiosity and cau­ tion.

This cover focus on GLP-1RAs features contributions from both medical and aesthetic dermatology experts, providing a balanced perspective on how these medications are affecting care across subspecialties. It also includes insights from der­ matology residents, who, as our future leaders, must become fluent in the interdisciplinary tools that will shape clinical practice.

We are only beginning to understand the implications of GLP-1s for skin and systemic health. These medications are here to stay, and dermatology must be part of the conversation. n

—Ted Lain, MD, MBA, FAAD

Guest Medical Editor